Astellas Pharma Global Development, Inc.

This study tested a new drug called ASP2074 in 23 adults with advanced solid tumors that had spread or couldn't be removed. The goal was to find a safe dose and check for side effects. The study was stopped early, so results are limited.

This early-phase study tested a lab-modified virus called ASP1012 designed to infect and kill cancer cells while leaving healthy cells alone. It also helps the immune system recognize and attack the cancer. The study included 15 adults with advanced solid tumors who had exhausted…

This study tested a drug called enfortumab vedotin for people with a type of bladder cancer that hasn't spread into the muscle layer. The drug was placed directly into the bladder using a thin tube. The main goals were to check for side effects and see how the body handles the dr…

This study tested an experimental drug called enfortumab vedotin, alone or with other cancer treatments, in people with advanced bladder or urinary tract cancer. The goal was to see if the drug could shrink tumors and to monitor side effects. The study included 348 participants b…

This early-phase study tested a new treatment called ASP2802 for adults with CD20-positive B-cell lymphoma that returned or stopped responding to prior therapy. The treatment involves collecting a patient's own immune cells, modifying them to better fight cancer, and giving them …

This early-stage study tested a new drug called ASP5502 in healthy adults and people with primary Sjögren's syndrome, a condition where the immune system attacks moisture-producing glands. The main goal was to check safety and how well the drug is tolerated. The study was stopped…

This study tested a drug called gilteritinib, which targets a specific genetic change (FLT3/ITD) in acute myeloid leukemia (AML), combined with standard chemotherapy. It included children, teens, and young adults whose leukemia had come back or didn't respond to treatment. The go…